The global neurodegenerative disease market size is expected to be valued at USD 52.08 billion by 2024. The market valuation is estimated to be USD 102.4 billion by 2034, projected at a CAGR of 7%.
The rise in prevalence and incidence rates of major neurodegenerative diseases and advancements in medical research and technology propel growth. With a growing elderly population worldwide, the incidence and prevalence of neurodegenerative diseases like Alzheimer’s and Parkinson’s are rising, creating a substantial demand for diagnostic tools, treatments, and supportive care services.
Get Sample PDF of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1052
Ongoing research efforts and technological innovations are leading to the development of novel therapies targeting the underlying mechanisms of neurodegenerative diseases, fostering market expansion.
The high cost of research and development, along with the lengthy and expensive clinical trial process for new therapies, poses financial challenges for companies operating in this space. Regulatory hurdles and market access barriers may hinder the commercialization of innovative treatments.
The complexity of neurodegenerative diseases, characterized by multifactorial etiology and heterogeneous clinical manifestations, further complicates diagnosis and treatment, presenting significant challenges for healthcare providers and researchers.
Despite these restraints, the neurodegenerative disease market offers numerous opportunities for growth. The rise in focus on personalized medicine approaches, leveraging biomarkers and genetic testing, presents opportunities to tailor treatments to individual patients, improving efficacy and reducing adverse effects.
The adoption of digital health solutions, such as wearable devices and telemedicine platforms, enhances disease management and patient care, propelling market expansion.
Key Takeaways from the Market Study:
- Based on the drug class, the immunomodulators segment is accounted to hold a market share of 43.4% in 2024.
- The United States is expected to register at a CAGR of 6.9% by 2034.
- The United Kingdom registers significant growth, projected at a CAGR of 8.6% by 2034.
- Based on disease indication, the Alzheimer’s disease segment is accounted to hold a market share of 32.2% in 2024
“The aging population serves as a fundamental driver shaping the growth trajectory of the global neurodegenerative disease industry. As the global population ages, the prevalence of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s rises significantly,” comments a Future Market Insights analyst.
Request Customization of Report: https://www.futuremarketinsights.com/customization-available/rep-gb-1052
Competitive Landscape:
The competitive landscape of the global neurodegenerative disease industry is characterized by intense competition among pharmaceutical companies, biotechnology firms, and research institutions.
Key players focus on developing innovative therapies for conditions like Alzheimer’s and Parkinson’s, while strategic collaborations and mergers drive market consolidation and innovation.
Recent developments are:
- In 2023, Boehringer Ingelheim Group announced positive results from a Phase II clinical trial evaluating their novel compound for the treatment of Alzheimer’s disease. The compound demonstrated promising efficacy in reducing cognitive decline and disease progression, offering hope for patients and clinicians grappling with this challenging condition.
- In 2023, Biogen Idec, Inc. achieved a significant milestone in the neurodegenerative disease market with the FDA approval of their novel therapy for the treatment of amyotrophic lateral sclerosis (ALS). This approval marked a breakthrough in ALS treatment, offering new hope for patients grappling with this devastating condition.
Key Companies Profiled:
Novartis AG; Pfizer Inc.; Merck Serono; Biogen Idec; Teva Pharmaceuticals; UCB; Boehringer Ingelheim; Sanofi S.A; GlaxoSmithKline
Key Segments:
By Drug Class:
The market is classified into N-methyl-D-aspartate (NMDA), Selective Serotonin Reuptake Inhibitors (SSRIs), Dopamine Inhibitors, and Immunomodulators.
By Disease Indication:
The report consists of key sourcing, such as Parkinson’s Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Huntington Disease.
By Region:
Analysis of the market has been carried out in key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe, and the Middle East and Africa.
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/1052
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
